Plain language summary of clinical research examining burosumab safety in young patients with X-linked hypophosphatemia

This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases examines X-linked hypophosphatemia (XLH), a rare genetic disorder affecting phosphate levels and causing bone deformities and growth issues. Since burosumab’s safety data was incomplete, researchers analyzed treatment outcomes in children and adolescents through the International XLH Registry to better understand the drug’s safety profile.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis’ and was published in Sage Open Chronic Disease.

Visit Sage using the link to read the original article.

• adolescents
• burosumab
• children
• Patient registry
• plain language summary
• post-authorization safety study (PASS)
• rare disease
• Renal phosphate-wasting disorder
• X‑linked hypophosphatemia (XLH)